Monday 31 January 2022

GSK to transition North American fleet to 100% EVs by 2030

GlaxoSmithKline (GSK) is to transition its fleet in North America to 100% electric vehicles (EVs) by 2030.

It is part of the pharmaceutical company's commitment to the EV100 initiative, a global initiative bringing together companies committed to switching their own and contracted fleets to EVs and installing charging infrastructure for employees and customers over the next decade.

GSK is partnering with ARI and Enel X for the deployment of EVs and the installation of more than 100 charging stations.

Together, the companies, with installation support from Qmerit, are providing GSK with a turnkey fleet management and sustainability solution, which includes JuiceBox smart charging stations and IoT software to help effectively manage the EV fleet.

The smart charging stations can be scheduled to use off-peak charging, which delivers energy cost savings and reduces strain on the grid during peak times.

Henry Rogers, Director of Fleet, GSK said: “As a global science-based healthcare company, GSK knows the importance of protecting and restoring the planet's health in order to protect and improve people's health.

“Our goal is to have a net zero impact on climate by 2030 and the EV100 initiative aims to deliver benefits to both climate and health by reducing air pollution from vehicles. This is an exciting step for our commercial fleet that also provides a seamless experience for our people.”